deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT03553875

Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions

Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions: A Randomized-controlled Trial

Sponsor: Massachusetts General Hospital

Conditions Autism Autism Spectrum Disorder Nonverbal Learning Disability
Interventions Memantine Hydrochloride Placebo
Updated 18 times since 2018 Last updated: Feb 24, 2026 Started: Nov 13, 2018 Primary completion: Nov 25, 2025 Completion: Nov 25, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

requested by the IRB

Other terminated trials from Massachusetts General Hospital

See all terminations from Massachusetts General Hospital

This PHASE3 trial investigates Autism and Autism Spectrum Disorder and is currently terminated or withdrawn. Massachusetts General Hospital leads this study, which shows 18 recorded versions since 2018 — indicating substantial longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Jul 2019 · 8 months · monthly snapshot~Jul 2019 – ~Dec 2019 · 5 months · monthly snapshot~Dec 2019 – ~Sep 2020 · 9 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Oct 2023 · 13 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Aug 2025 · 10 months · monthly snapshot~Aug 2025 – ~Feb 2026 · 6 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

18 versions recorded

  1. Feb 2026 — Present [monthly]

    Terminated PHASE3

    Status: Suspended → Terminated

  2. Aug 2025 — Feb 2026 [monthly]

    Suspended PHASE3

  3. Oct 2024 — Aug 2025 [monthly]

    Suspended PHASE3

    Status: Recruiting → Suspended

  4. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

▶ Show 13 earlier versions

  1. Oct 2023 — Jul 2024 [monthly]

    Recruiting PHASE3

  2. Sep 2022 — Oct 2023 [monthly]

    Recruiting PHASE3

  3. Sep 2021 — Sep 2022 [monthly]

    Recruiting PHASE3

  4. Mar 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  5. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE3

  6. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE3

  7. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  8. Dec 2019 — Sep 2020 [monthly]

    Recruiting PHASE3

  9. Jul 2019 — Dec 2019 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  10. Nov 2018 — Jul 2019 [monthly]

    Not Yet Recruiting PHASE3

  11. Oct 2018 — Nov 2018 [monthly]

    Not Yet Recruiting PHASE3

  12. Sep 2018 — Oct 2018 [monthly]

    Not Yet Recruiting PHASE3

  13. Jul 2018 — Sep 2018 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Massachusetts General Hospital
Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations